Beam expects that its cash, cash equivalents and marketable securities as of March 31, 2025, including net proceeds from the recent $500 million financing, will enable the company to fund its anticipated operating expenses and capital expenditure requirements into 2028. This expectation includes funding directed toward reaching each of the key anticipated milestones for BEAM-101, ESCAPE, BEAM-301 and BEAM-302 described above.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAM:
- JPMorgan biotech/Euro pharma analysts hold analyst/industry conference call
- Cathie Wood’s ARK Investment buys 135K shares of Beam Therapeutics today
- Beam Therapeutics’ BEAM-302: Promising Clinical Data and Market Potential Drive Buy Rating
- Beam Therapeutics presents additional data for BEAM-302 in AATD
- Cathie Wood’s ARK Investment buys 143K shares of Beam Therapeutics today